ArticleScientific reports2025
TMBIM6 promotes glioma progression according to integrated bioinformatics and experimental evidence.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
TMBIM6, a transmembrane BAX inhibitor motif containing 6, located in the endoplasmic reticulum, is linked to various cellular processes and cancer progression. Previous investigations showed a substantial association between TMBIM6 and survival in patients diagnosed with various cancer types. However, the lack of extensive studies addressing the correlation between TMBIM6 and gliomas necessitates a comprehensive investigation to explore its potential as a prognosis marker for glioma. This study investigates TMBIM6's prognostic value by using data from TCGA (The Cancer Genome Atlas), GEO (Gene Expression Omnibus), and CGGA (Chinese Glioma Genome Atlas) databases, along with histopathological analysis of tissue microarray slide. Survival analysis confirmed the prognostic significance of TMBIM6 in glioma, while co-expression analysis identified positively and negatively correlated genes with TMBIM6, and Enrichment analysis suggested TMBIM6's association with protein processing in the ER and NOD-like receptor signaling pathways. A strong correlation was observed between TMBIM6 expression and immune infiltration, especially with M2 macrophages. Additionally, hsa-miR-128-3p was identified as an upstream regulator of TMBIM6. These findings highlight TMBIM6's potential as a prognostic biomarker for glioma, offering new insights into its role in glioma progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.